ProteaBio Europe SAS, a leading developer of new technology, announced today that the company has concluded an exclusive, worldwide license agreement with George Washington University for commercial rights to a new technology that provides rapid identification of a broad range of chemicals and biomolecules.
“We foresee a broad range of applications in chemical and biological research, surgical pathology, clinical diagnostics, chemical and biological defense, forensics, agriculture, and many other fields. LAESI is a breakthrough technology of the first order”
Known as Laser Ablation Electrospray Ionization or "LAESI" mass spectrometry, the technology is capable of directly identifying proteins, peptides, lipids, and metabolites found in biological samples, including tissue, blood, urine and even single cells. Extremely rapid (less than 2 seconds per analysis), sensitive and quantitative, LAESI also provides 3 dimensional mapping of biomolecules through depth profiling and lateral imaging. Proteins and metabolites can be identified and localized in cell structures, tissues and fluids.
LAESI technology was invented and developed in the laboratory of Dr. Akos Vertes Ph.D., Professor of Chemistry, Professor of Biochemistry & Molecular Biology, and Founder and Co-Director of the W.M. Keck Institute for Proteomics Technology, at the Department of Chemistry, George Washington University.
"We believe LAESI technology holds the promise to meet the great need of biologists and medical professionals", stated Daniel Dupret, ProteaBio's President. He added, "We foresee a broad range of applications in chemical and biological research, surgical pathology, clinical diagnostics, chemical and biological defense, forensics, agriculture, and many other fields. LAESI is a breakthrough technology of the first order"
Professor Vertes commented, "LAESI represents a minimally invasive and minimally destructive approach to chemical analysis, which means that dynamic, even living cells or tissues can be probed for their molecular composition not only in three dimensions, but also with time. Small sample consumption of the LAESI analysis means that much of the sample remains available for additional investigation."
In collaboration with the Vertes laboratory, Protea scientists are developing instrumentation and software that will bring the capabilities of the LAESI technology to research laboratories worldwide, beginning in 2011.
Advances and hurdles: The impact of AI on oncology care efficiency and mortality rates